Research
Hormonal
Triple agonists (retatrutide, SAR441255) demonstrate superior efficacy in reversing fatty liver disease (MASH) compared to dual agonists and GLP-1 monotherapy.
For those with fatty liver disease (MASH), triple agonists like retatrutide have shown remarkable ability to normalize liver fat in 90% of patients in clinical trials. This makes them a promising treatment option for liver health, beyond just weight loss.
ModerateSupportsMEDIUM confidence
After 48 weeks treatment with two highest doses of retatrutide, 90% of participants had normalisation of liver fat
Why this rating
Based on a substudy of a Phase 2 trial, not a dedicated Phase 3 MASH trial.
Source
The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
Agnieszka Jakubowska et al. · Endocrinology and Metabolism · 2024
DOI 10.3803/enm.2024.1942
narrative_reviewCited 36×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Triple agonist retatrutide (GLP-1/GIP/glucagon) produces superior weight loss (up to 24.2% at 12mg) compared to dual agonists and GLP-1 monotherapy, driven by synergistic activation of all three receptors.Good
- Glucagon receptor activation in triple agonists increases energy expenditure and lipid oxidation, contributing to weight loss without causing hyperglycemia when combined with GLP-1 and GIP.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →